Drug Insights

Is Rimegepant approved by the FDA?

27 June 2024
3 min read

Yes, Rimegepant is FDA approved. The U.S. Food and Drug Administration (FDA) approved Rimegepant, under the brand name Nurtec ODT, on February 27, 2020. This medication belongs to the drug class of CGRP (calcitonin gene-related peptide) inhibitors.

What is Rimegepant?

Rimegepant is a prescription medication used for the acute treatment of migraines, with or without aura, in adults. Additionally, it is used to prevent episodic migraines. This medication helps alleviate symptoms such as headache, nausea, vomiting, and sensitivity to light and sound by blocking CGRP receptors.

How Does Rimegepant Work?

Rimegepant works by targeting and blocking the CGRP receptors, which play a significant role in migraine pathophysiology. By inhibiting these receptors, Rimegepant helps reduce migraine symptoms and, when taken regularly, can decrease the frequency of migraine attacks.

Dosage and Administration

Rimegepant is administered as an orally disintegrating tablet (ODT), which dissolves in the mouth without the need for water. The typical dosage is 75 mg, and the tablet should be taken as follows:

  • Place the tablet on or under the tongue and allow it to disintegrate in saliva before swallowing.
  • Do not take more than one tablet in a 24-hour period.

Usage Guidelines

  • Acute Treatment: Take one tablet as soon as migraine symptoms appear.
  • Preventive Treatment: Regular use can help reduce the number of migraine days each month.

Warnings and Precautions

  • Frequency: Do not exceed treating more than 15 migraines in a 30-day period.
  • Allergies: Avoid use if allergic to Rimegepant.
  • Medical Conditions: Inform your healthcare provider if you have liver or kidney disease.
  • Pregnancy and Breastfeeding: The safety of Rimegepant during pregnancy and breastfeeding is not well-established. Consult your doctor for advice.

Side Effects

Common side effects of Rimegepant include:

  • Nausea
  • Allergic reactions (hives, rash, difficulty breathing, swelling of the face, lips, tongue, or throat)

Drug Interactions

Rimegepant can interact with other medications, affecting its efficacy and increasing side effects. Avoid taking Rimegepant within 48 hours of using the following:

  • Aprepitant
  • Erythromycin
  • Fluconazole
  • Heart or blood pressure medications like diltiazem and verapamil

Storage

Store Rimegepant at room temperature, away from moisture and heat. Keep it in its original blister pack until ready for use.

Conclusion

Rimegepant (Nurtec ODT) is an FDA-approved medication for the acute treatment and prevention of migraines in adults. Approved on February 27, 2020, it provides a quick-dissolving, effective option for managing migraine symptoms and reducing the frequency of episodic migraines. Always consult with a healthcare provider for personalized advice and follow all prescribed guidelines for safe and effective use.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Scholar Rock Reveals SRK-439 Data: Preserves Lean Mass, Reduces Fat Mass Rebound Post-GLP-1 Agonist
Latest Hotspot
3 min read
Scholar Rock Reveals SRK-439 Data: Preserves Lean Mass, Reduces Fat Mass Rebound Post-GLP-1 Agonist
27 June 2024
Scholar Rock Unveils New SRK-439 Preclinical Data Showing Notable Lean Mass Preservation and Reduced Fat Mass Rebound After Stopping GLP-1 Receptor Agonist.
Read →
Is Nexlizet approved by the FDA?
Drug Insights
3 min read
Is Nexlizet approved by the FDA?
27 June 2024
The U.S. Food and Drug Administration (FDA) approved Nexlizet, a combination of bempedoic acid and ezetimibe, on February 26, 2020.
Read →
Altimmune Reveals Pemvidutide's Effects on Cardioinflammatory Lipids at ADA's 84th Session
Latest Hotspot
3 min read
Altimmune Reveals Pemvidutide's Effects on Cardioinflammatory Lipids at ADA's 84th Session
27 June 2024
Altimmune Shares Findings on Pemvidutide's Impact on Cardioinflammatory Lipid Levels at ADA’s 84th Annual Scientific Sessions.
Read →
Is Bempedoic acid approved by the FDA?
Drug Insights
3 min read
Is Bempedoic acid approved by the FDA?
27 June 2024
The U.S. Food and Drug Administration (FDA) approved bempedoic acid on February 21, 2020.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.